Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis-Reference-Cited by-同舟云学术

Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis

Published:2020-12-03 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Jakob Tina¹,Tesfamariam Yonas Mehari¹,Macherey Sascha²,Kuhr Kathrin³,Adams Anne³,Monsef Ina¹,Heidenreich Axel⁴,Skoetz Nicole⁵

Affiliation:

1. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

2. University of Cologne; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematological Malignancies; Cologne Germany

3. Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

4. Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department of Urology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

5. Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference152 articles.

1. Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebo-control trial;*Abetz;Journal of Clinical Oncology,2006

2. Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status;Barghout;Journal of Clinical Oncology - Supplement,2006

3. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance);*Smith;Journal of Clinical Oncology,2014

4. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer;Cook;Clinical Cancer Research,2006

5. CALGB 90202: a randomized double-blind, placebo-controlled phase III study of early vs standard zoledronic acid to prevent skeletal-related events in men with prostate cancer metastatic to the bone;Smith;Clinical Advances in Hematology and Oncology,2006

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a core outcome set of clinical research on the integration of traditional Chinese and Western medicine for spinal metastases:a study protocol;BMJ Open;2024-09

2. The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence;Frontiers in Oncology;2024-08-01

3. Investigating the Underlying Molecular Mechanisms of Yunke on Bone Metastases from Prostate Cancer;Biologics: Targets and Therapy;2024-07

4. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies;ESMO Open;2024-07

5. Electromembrane extraction of pharmaceutical analytes: Systematic review and meta-analysis;Separation and Purification Technology;2024-06